Tekla Life Sciences Investors

Tekla Life Sciences Investors

HQLยทNYSE

$16.93

-1.5%
Financial ServicesAsset Management

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

At a Glance

Live Snapshot
Market Cap$514.81M
EPS2.9600
P/E Ratio5.72
Earnings Date06/24/2025
3Y+171.0%
5Y+121.0%
10Y+1273.0%
3Y-182.0%
5Y-30.0%
10Y-819.0%
Tekla Life Sciences Investors

Tekla Life Sciences Investors Profit Bridge

HQL ยท NYSE
Revenue86.39M
Cost of Goods Sold (0.00)
Gross Profit86.39M
Operating Expenses (791.57K)
Operating Income85.59M
Interest Expense (0.00)
Other Income/Expense0.00
Pretax Income85.59M
Income Tax (0.00)
Net Income85.59M
Net Income
85.59M

Profitability Analysis

Gross Margin

100.0%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

99.1%

Outstanding operational efficiency. The company generates substantial profit from core operations.

Net Profit Margin

99.1%

Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.

Effective Tax Rate

0.0%

Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.

Profitability Insight

Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.

Tekla Life Sciences Investors Income Statement

HQL โ€ข NYSE

Tekla Life Sciences Investors Income StatementSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017Sep 2016Sep 2015Sep 2014Sep 2013Sep 2012Sep 2011Sep 2010Sep 2009Sep 2008Sep 2007Sep 2006
REVENUE
86.4M
86.7M
39.4M
31.9M
45M
39.1M
2.4M
2M
69.8M
6.3M
1.3M
876.8K
516.8K
2.1M
570K
1.8M
460K
1.7M
2.9M
2.3M
GROSS PROFIT
(0.0)
(0.0)
(5.2M)
(5.5M)
(6.1M)
(5.2M)
(0.0)
(0.0)
(4.6M)
(4.9M)
(5.6M)
(4.1M)
(3.1M)
(2.5M)
(3M)
(3M)
(2.9M)
(3.8M)
(3.6M)
(2.9M)
86.4M
86.7M
18.3M
26.3M
38.9M
33.9M
2.4M
2M
65.2M
1.3M
-4.3M
-3.3M
-2.6M
-335.5K
-2.5M
-1.2M
-2.4M
-2.1M
-740K
-630K
OPERATING INCOME
(791.6K)
(1.4M)
(1.2M)
(1.4M)
(1.2M)
(1M)
(5.3M)
(5.6M)
(1.3M)
(13.3M)
(39.2M)
(88.4M)
(84.1M)
(75.5M)
(1.4M)
(790K)
(760K)
(820K)
(970K)
(710K)
(743.2K)
(1.3M)
(903.1K)
(1.1M)
(844K)
(751.3K)
(5.3M)
(5.6M)
(991.5K)
-1.0
(6M)
(4.6M)
(3.7M)
(3.4M)
(1.2M)
(630K)
(590K)
(680K)
(720K)
(550K)
(0.0)
(0.0)
(0.0)
-3.0
(0.0)
(3.0)
(0.0)
(0.0)
(1.0)
-1.0
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
85.6M
85.3M
-5.2M
-104.6M
64.5M
123.1M
-2.9M
-3.6M
-3.9M
-3.8M
-4.7M
-3.8M
-3.2M
-1.3M
-3.8M
-2M
-3.2M
-2.9M
-1.7M
-1.3M
PRE-TAX INCOME
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(45.2M)
(93M)
(87.8M)
(78.9M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
349.8K
1M
204.4K
50.1K
0.0
164.8K
0.0
0.0
90.6K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
(48.4K)
(56.7K)
(268.3K)
(276K)
(313.7K)
(278.7K)
(0.0)
(0.0)
(423.3K)
(20.7M)
(143.4K)
(130K)
(150K)
(200K)
(200K)
(160K)
(170K)
(140K)
(250K)
(160K)
0.0
87.2M
27.6M
2.4K
-7.8K
-11.2K
-67.6M
32.3M
72.7M
-8.1M
45.2M
93M
87.8M
78.9M
41.3M
12.2M
-18.5M
63.2M
52.2M
-20.1M
85.6M
85.3M
22.4M
-104.6M
64.5M
123.1M
-70.5M
28.7M
68.6M
-11.9M
40.5M
89.3M
84.6M
77.6M
37.5M
10.2M
-21.7M
60.3M
50.5M
-21.4M
NET INCOME
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(3.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
85.6M
85.3M
22.4M
-104.6M
64.5M
123.1M
-70.5M
28.7M
68.6M
-11.9M
40.5M
89.3M
84.6M
77.6M
37.5M
10.2M
-21.7M
60.3M
50.5M
-21.4M

SEC Filings

HQL - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
DEF 14A

DEF 14A 2024

N/A

April 22, 2024
June 25, 2024
2024
8-K

8-K 2023

N/A

September 12, 2023
September 06, 2023
2023
DEF 14A

DEF 14A 2023

N/A

April 11, 2023
June 08, 2023
2023
DEF 14A

DEF 14A 2022

N/A

April 12, 2022
June 09, 2022
2022
DEF 14A

DEF 14A 2019

N/A

April 15, 2019
June 13, 2019
2019
DEF 14A

DEF 14A 2018

N/A

April 18, 2018
June 14, 2018
2018
DEF 14A

DEF 14A 2017

N/A

April 18, 2017
June 15, 2017
2017
DEF 14A

DEF 14A 2014

N/A

April 30, 2014
June 09, 2014
2014
DEF 14A

DEF 14A 2013

N/A

April 25, 2013
June 04, 2013
2013
8-K

8-K 2013

N/A

March 25, 2013
March 22, 2013
2013
Showing 1 to 10 of 21 filings